BXYRegulatory•globenewswire•
BioXcel Therapeutics Announces Positive FDA Pre-sNDA Meeting Comments for sNDA Submission for BXCL501 in Agitation Associated with Bipolar Disorders or Schizophrenia
Sentiment:Positive (75)
Summary
Achieved alignment with the FDA on sNDA package to expand the IGALMI label for the At-Home (Outpatient) setting
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on August 18, 2025 by globenewswire